Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Boldenone is a synthetic anabolic–androgenic steroid (AAS) and a derivative of testosterone developed primarily for veterinary use, especially in horses[1][2][3]. It is not approved for human use in the United States or most other countries. Boldenone acts as an agonist of the androgen receptor and exerts its effects by regulating gene transcription after binding to this receptor[1][3]. Its activity is mainly anabolic with relatively low androgenic potency. The drug increases nitrogen retention and protein synthesis, stimulates appetite, and promotes erythropoietin release from the kidneys[2][3]. While originally developed for medical purposes (with early clinical formulations such as Parenabol), it was discontinued for human use due to lack of therapeutic benefit and potential side effects. Currently, boldenone undecylenate (a long-lasting ester form) remains available under brand names like Equipoise for veterinary applications but is also misused illicitly by athletes seeking performance enhancement[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on boldenone.